Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early ...

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved in the European Union (EU) as first-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC ...

The long-term effects of gallbladder removal are usually positive, alleviating chronic pain associated with cholecystitis (gallbladder inflammation) while reducing the risk of gallstones. However, ...